Clinical Trials Logo

Thrombotic Stroke clinical trials

View clinical trials related to Thrombotic Stroke.

Filter by:

NCT ID: NCT06275139 Recruiting - Coronary Disease Clinical Trials

Integrated Assessment of Cervicocerebral Vessels to Improve the Brain Injury for CAGB Patients (IACV Study)

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to establish a prospective study to focus on the high-risk stroke population who require coronary artery bypass graft surgery. It will divide the eligible patients into 1:1 group by simple randomization method. The control group adopt the traditional diagnosis and treatment mode, and only head CT plain scan and carotid artery ultrasound shall be performed. If necessary, relevant disciplines would be consulted but no integrated assessment of cervicocerebral vessels be arranged. The final treatment plan would be decided by the surgeon alone. The experimental group adopt the multidisciplinary collaboration and integrated evaluation mode. In addition to routine diagnosis and treatment as above-mentioned, integrated assessment of cervicocerebral vessels shall be performed, including transcranial color-coded doppler, cerebral perfusion with multislice CT, and cognitive function assessment. Based on the above results, surgical plans will be formulated jointly by multiple disciplines including neurologists, vascular surgeons, ICU physicians and cardiac surgeons. Researchers will compare the two groups to investigate whether integrated assessment of cervicocerebral vessels can reduce the incidence of brain injury compared with conventional diagnosis and treatment mode.

NCT ID: NCT06156059 Not yet recruiting - Septic Shock Clinical Trials

Oral Bedtime Melatonin in Critically Ill Patients

Mel-ICU
Start date: February 1, 2025
Phase: Phase 4
Study type: Interventional

Oxidative stress is one of the main mechanisms causing harm in severe infection with septic shock, ischemia-reperfusion injury in resuscitated cardiac arrest and ischemic and hemorrhagic stroke. Melatonin is a potent scavenger of the mediators of oxidative stress, oxygen and nitrogen-reactive species, which directly injure cell structures like walls and DNA and thus cause organ dysfunction. In a previous study we have observed that high-dose oral bedtime melatonin (OBM) is associated with improved organ function in severe Covid-19 patients

NCT ID: NCT06034847 Not yet recruiting - Clinical trials for Stroke, Acute Thrombotic

Treatment of Persistent Distal Occlusion After Successful Proximal Recanalization in Thrombectomy

2BE3
Start date: January 2024
Phase: N/A
Study type: Interventional

In stroke patients, mechanical thrombectomy is now the standard of care when the stroke is due to large proximal cerebral vessel occlusion. The purpose of the 2BE3 trial is to test whether adjunct rescue treatment of persisting distal occlusions after successful proximal recanalization of the large vessel occlusion can be proposed as an additional intervention to restore reperfusion of affected stroke tissue and improve clinical outcomes. The rescue therapies will be either mechanical (small stent retrievers and/or small aspiration catheters) or pharmacological (infusion of intra-arterial thrombolytics). Patients will be randomized to conservative management (mechanical thrombectomy with or without IV thrombolytics of large proximal vessels) or rescue therapy (mechanical or pharmacological interventions in distal vessels in addition to conservative management). Each patient will be followed for 3 months post-intervention. The data collected will be clinical assessments and angiographic imaging to evaluate the reperfusion state.

NCT ID: NCT05857046 Recruiting - Clinical trials for Stroke, Acute Ischemic

Cerebroprotective Effect of Melatonin in Stroke

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

Stroke is a leading cause of mortality and disability in Mexico and worldwide. Although current treatment strategies focus on removing oclussion, they do not interrupt the signaling cascade of neuronal damage. Thus, the search for a cerebroprotective agent that can protect the entire brain. Melatonin has been proposed as a potential cerebroprotective agent due to its antioxidant, anti-inflammatory, antiapoptotic, and immunomodulatory effects, which oppose the pathophysiological mechanisms of cerebrovascular disease. Melatonin has the potential to improve stroke outcomes and reduce the risk of disability and mortality, making it a promising therapeutic option for stroke patients. To assess the efficacy of melatonin in patients with acute ischemic CVD, improve clinical outcome, and infarct volume.

NCT ID: NCT05417009 Completed - Ischemic Stroke Clinical Trials

Autonomic Neuromodulation by Transcutaneous Nerve Stimulation in Acute Ischaemic Stroke.

VANS
Start date: April 26, 2023
Phase: N/A
Study type: Interventional

Autonomic modulation by transcutaneous vagal nerve stimulation in acute ischaemic stroke requiring mechanical thrombectomy: a phase IIa, sham controlled randomised trial.

NCT ID: NCT05325606 Recruiting - Stroke Clinical Trials

Registry-based Stroke in Tunisia

RAV-TUN
Start date: June 1, 2020
Phase:
Study type: Observational [Patient Registry]

Study the prevalence of strokes in the emergency department (ED) and their possible eligibility for thrombolysis.

NCT ID: NCT05289947 Recruiting - Stroke Clinical Trials

MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits

MAESTOSO
Start date: July 21, 2023
Phase: Phase 2
Study type: Interventional

This is a multi-center, randomized, double-blind, placebo-controlled trial of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 high-dose twice a day, MLC1501 low-dose twice a day, or matching placebo for 24 weeks.

NCT ID: NCT05046106 Not yet recruiting - Stroke Clinical Trials

MLC1501 Study Assessing Efficacy in STROke Recovery

MAEStro
Start date: January 2025
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a day, MLC1501 high-dose twice a day, or matching placebo for 24 weeks.

NCT ID: NCT04769310 Recruiting - Stroke Clinical Trials

Advanced Cardiac Imaging To Predict Embolic Stroke On Brain MRI: A Pilot Study

Start date: April 26, 2021
Phase: N/A
Study type: Interventional

Demonstrating the pathophysiological link between Left Atrial (LA) and Left Atrial Appendage (LAA) pathology and embolic strokes in non-Atrial Fibrillation (AF) individuals represents a major advance in stroke prevention strategies. Instead of relying on non-specific criteria for stroke risk assessment, the investigators propose to identify individuals with high-risk of embolic stroke using imaging criteria that reflect the underlying pathophysiology of embolic stroke of cardiac origin. the investigators can therefore lay the groundwork for future anticoagulation strategies for stroke prevention beyond AF.

NCT ID: NCT03897478 Recruiting - Stroke Clinical Trials

Biomarkers of Acute Stroke in Clinic

BASIC
Start date: April 1, 2019
Phase:
Study type: Observational

The proposed study will investigate the clinical use of the ISCDX test that may differentiate between diverse stroke etiologies as listed below: Aim 1: Differentiate between cardioembolic and large artery atherosclerotic ischemic strokes, when hemorrhagic stroke is ruled out, as defined by TOAST classification of subtypes of acute ischemic stroke. Aim 2: In cases of ischemic strokes of unknown or "cryptogenic" etiology, determine the ability of biomarker blood tests to predict etiology between cardioembolic and large artery atherosclerotic.